| Clinical data | |
|---|---|
| Other names | IPRLAD; IP-LAD; IPLAD; 6-Isopropyl-6-nor-LSD; 6-Isopropyl-6-nor-lysergic acid diethylamide |
| Routes of administration | Oral |
| Drug class | Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H29N3O |
| Molar mass | 351.494 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
IP-LAD, or IPLAD, also known as IPR-LAD or as 6-isopropyl-6-nor-LSD, is an analogue of lysergic acid diethylamide (LSD) developed by the team of David E. Nichols.12 In studies on mice, it was found to be approximately 40% the potency of LSD, compared to the 60% increase in potency seen with ETH-LAD, 2-fold potency increase of AL-LAD, and roughly equivalent potency of PRO-LAD.2 It is not a controlled substance in Canada as of 2025.3
References
References
- Nichols DE, Oberlender R, McKenna DJ (1991). "Stereochemical Aspects of Hallucinogenesis". In Watson RR (ed.). Biochemistry and Physiology of Substance Abuse. Vol. 3. Boca Raton, Fla.: CRC Press. pp. 1–39. ISBN 978-0-8493-4463-3. OCLC 26748320.
TABLE 1 Effects of N-(6)-Alkyl Subtituents on LSD-Like Behavior and Serotonin Receptor Affinity in Rats [...]
- Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID 4032428.
- "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.